Anaveon announces poster presentation at the 2025 American College of Rheumatology Convergence
— Anaveon will present ANV200, a novel, highly potent Fc-engineered anti-PD-1 agonistic antibody designed to deplete pathogenic T cells expressing high to low levels of PD-1 —
Basel, October 27, 2025 – Anaveon, a global clinical stage, immunology company, will present a poster on ANV200 at the American College of Rheumatology (ACR) Convergence being held from Friday, October 24, 2025, to Wednesday, October 29, 2025, in Chicago, IL, USA.
ANV200 is a novel, Fc-enhanced anti-PD-1 agonistic antibody, engineered to drive robust and comprehensive depletion of PD-1-expressing pathogenic T cells which may achieve deeper clinical responses in autoimmune diseases.
The abstract is available on the ACR website. The accompanying poster can be found on the ACR 2025 meeting platform and is posted on Anaveon’s website (download poster here).
Poster # P0990 – An Fc-engineered agonistic Anti-PD-1 Antibody Selectively Depletes PD-1+ cells and Attenuates T cell activation in vitro and in vivo in a Xenogeneic GvHD model
Authors: L. Pouzol, P. Murer, N. Egli, L. Petersen, A. Zurbach, C. Stocker, A. Rau, A. Katopodis, C. Huber
The Poster will be presented on Monday, October 27, 2025, between 10:30 am and 12:00 pm CDT.
Anaveon’s mission is to harness the power of the immune system for life-changing treatments. The company was founded in 2017 by scientists and industry experts, who aspire to invent and develop therapeutic treatments that benefit patients and society. Today, Anaveon is a clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. Our team is driven to make this vision a reality: we are committed to transforming immunological insights into life-changing therapies.
ENDS
Media contact:
Benz Advisory
Beatrix Benz
Email: beatrix.benz@benz-advisory.com
Tel: +41 79 256 77 73
About Anaveon:
Anaveon is an international biotechnology company located in Basel, Switzerland. Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compound ANV600 is currently in clinical trials in solid tumors.
Find out more at anaveon.com
